Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Pomat, William S ^a,b   van den Biggelaar, Anita H J ^b,f   Phuanukoonnon, Suparat ^a   Francis, Jacinta ^a   Jacoby, Peter ^b   Siba, Peter M ^a   Alpers, Michael P ^c   Reeder, John C ^a,d   Holt, Patrick G ^b   Richmond, Peter C ^e   Lehmann, Deborah ^b  

^a Papua New Guinean Institute of Medical Research   (Papua New Guinea)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MATERNAL ANTIBODY; PNEUMOCOCCUS VACCINE;

AGE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL PNEUMONIA; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; INFANT; INFECTION PREVENTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; PAPUA NEW GUINEA; PNEUMONIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; UNSPECIFIED SIDE EFFECT;

EID: 84874319925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056698     Document Type: Article

References (54)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
3. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, et al. (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349: 1341-1348.
4. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, et al. (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146.
5. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, et al. (2003) Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362: 355-361.
6. O'Brien KL, Dagan R, (2003) The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21: 1815-1825.
7. Roche PW, Krause V, Cook H, Barralet J, Coleman D, et al. (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32: 18-30.
8. Black S, Shinefield H, Fireman B, Lewis E, Ray P, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187-195.
9. Global Alliance for Vaccines and Immunisation. GAVI Alliance website. Available: http://www.gavialliance.org/. Accessed 2012 Aug 1.
10. Moisi JC, Kabuka J, Mitingi D, Levine OS, Scott JA, (2010) Spatial and socio-demographic predictors of time-to-immunization in a rural area in Kenya: is equity attainable? Vaccine 28: 5725-5730.
11. Toikilik S, Tuges G, Lagani J, Wafiware E, Posanai E, et al. (2010) Are hard-to-reach populations being reached with immunization services? Findings from the 2005 Papua New Guinea national immunization coverage survey. Vaccine 28: 4673-4679.
12. O'Grady KA, Krause V, Andrews R, (2009) Immunisation coverage in Australian Indigenous children: time to move the goal posts. Vaccine 27: 307-312.
13. The WHO Young Infants Study Group (1999) Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis J 18: S17-S22.
14. Lehmann D, Yeka W, Rongap T, Javati A, Saleu G, et al. (1999) Aetiology and clinical signs of bacterial meningitis in children admitted to Goroka Base Hospital, Papua New Guinea, 1989-1992. Ann Trop Paediatr 19: 21-32.
15. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA, (2010) Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 201: 1570-1579.
16. Vakevainen M, Soininen A, Lucero M, Nohynek H, Auranen K, et al. (2010) Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 157: 778-783.
17. van den Biggelaar AH, Pomat WS, Phuanukoonnon S, Michael A, Aho C, et al. (2012) Effect of early carriage of Streptococcus pneumoniae on the development of pneumococcal protein-specific cellular immune responses in infancy. Pediatr Infect Dis J 31: 243-248.
18. Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, et al. (2009) Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol 16: 1633-1638.
19. Gratten M, Gratten H, Poli A, Carrad E, Raymer M, et al. (1986) Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers. Biol Neonate 50: 114-120.
20. Hill PC, Townend J, Antonio M, Akisanya B, Ebruke C, et al. (2010) Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 50: 1468-1476.
21. Lehmann D, Vail J, Firth MJ, de Klerk NH, Alpers MP, (2005) Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea. Int J Epidemiol 34: 138-148.
22. Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, et al. (2011) Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 53: 663-670.
23. Lehmann D, Marshall TF, Riley ID, Alpers MP, (1991) Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children. Ann Trop Paediatr 11: 247-257.
24. Pomat WS, Lehmann D, Sanders RC, Lewis DJ, Wilson J, et al. (1994) Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 62: 1848-1853.
25. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, et al. (1986) Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 2: 877-881.
26. Barker J, Gratten M, Riley I, Lehmann D, Montgomery J, et al. (1989) Pneumonia in children in the Eastern Highlands of Papua New Guinea: a bacteriologic study of patients selected by standard clinical criteria. J Infect Dis 159: 348-352.
27. Lehmann D, Willis J, Moore HC, Giele C, Murphy D, et al. (2010) The changing epidemiology of invasive pneumococcal disease in Aboriginal and non-Aboriginal Western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 50: 1477-1486.
28. Saha SK, Al Emran HM, Hossain B, Darmstadt GL, Saha S, et al. (2012) Streptococcus pneumoniae serotype-2 childhood meningitis in Bangladesh: a newly recognized pneumococcal infection threat. PLoS One 7: e32134.
29. Hill PC, Onyeama CO, Ikumapayi UN, Secka O, Ameyaw S, et al. (2007) Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infect Dis 7: 2.
30. Lehmann D, Gratten M, Montgomery J (1996) Report on data collected by the Papua New Guinea Institute of Medical Research to assist in determining whether antimicrobial susceptibility of bacterial isolates in the upper respiratory tract is a useful measure of antimicrobial susceptibility of isolates causing invasive disease. Report to the World Health Organization. Goroka: Papua New Guinea Institute of Medical Research.
31. Phuanukoonnon S, Reeder JC, Pomat WS, Van den Biggelaar AH, Holt PG, et al. (2010) A neonatal pneumococcal conjugate vaccine trial in Papua New Guinea: study population, methods and operational challenges. P N G Med J 53: 191-206. Papua New Guinea Institute of Medical Research website. Available: http://www.pngimr.org.pg/png_med_journal/sept-dec%202010%20a%20neonatal%20pneumococcal%20conjugate%20vaccine%20trials%20in%20png.pdf. Accessed 2012 Nov 4.
32. Kakazo M, Lehmann D, Coakley K, Gratten H, Saleu G, et al. (1999) Mortality rates and the utilization of health services during terminal illness in the Asaro Valley, Eastern Highlands Province, Papua New Guinea. P N G Med J 42: 13-26.
33. Papua New Guinea Department of Health (2005) Standard treatment for common illnesses of children in Papua New Guinea. A manual for nurses, community health workers, health extension officers and doctors. Port Moresby: Department of Health.
34. World Health Organization Pneumococcal Serology Reference Laboratories. Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). University of Alabama website. Available: http://www.vaccine.uab.edu/ELISAProtocol(89SF).pdf. Accessed 2012 May 10.
35. Gratten M, Montgomery J, (1991) The bacteriology of acute pneumonia and meningitis in children in Papua New Guinea: assumptions, facts and technical strategies. P N G Med J 34: 185-198.
36. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, et al. (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25: 3816-3826.
37. World Health Organization (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 1-29.
38. van den Biggelaar AH, Pomat W, Bosco A, Phuanukoonnon S, Devitt CJ, et al. (2011) Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance. Vaccine 29: 5414-5420.
39. van den Biggelaar AH, Richmond PC, Pomat WS, Phuanukoonnon S, Nadal-Sims MA, et al. (2009) Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea. Vaccine 27: 1340-1347.
40. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, et al. (2010) Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28: 4192-4203.
41. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205-212.
42. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
43. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, et al. (2010) Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2: 80-84.
44. Balloch A, Licciardi PV, Russell FM, Mulholland EK, Tang ML, (2010) Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol 126: 395-397.
45. Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, et al. (2011) The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 29: 2999-3007.
46. Russell FM, Licciardi PV, Balloch A, Biaukula V, Tikoduadua L, et al. (2010) Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 28: 3086-3094.
47. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, et al. (2012) Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 205: 1408-1416.
48. Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, et al. (2010) Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 28: 3341-3349.
49. Pomat W, Francis J, Orami T, Siba P, Greenhill A, et al. (2012) No evidence of hypo-responsiveness following re-challenge at 3-5 years in PNG children vaccinated with Pneumovax at 9 months. Eighth International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD8). Iguacu, Brazil.
50. Yoannes M, Michael A, Saleu G, Opa C, Greenhill A, et al. (2012) High pneumococcal carriage in 3-5 year old Papua New Guinean children following 9-month Pneumovax23 dose with or without prior 7-valent conjugate vaccine. Eighth International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD8). Iguacu, Brazil.
51. World Health Organization (1998) WHO meeting on maternal and neonatal pneumococcal immunization. Wkly Epidemiol Rec 73: 187-188.
52. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987.
53. Kumar D, Aggarwal A, Gomber S, (2010) Immunization status of children admitted to a tertiary-care hospital of north India: reasons for partial immunization or non-immunization. J Health Popul Nutr 28: 300-304.
54. Olusanya BO, (2010) Pattern and determinants of BCG immunisation delays in a sub-Saharan African community. Health Res Policy Syst 8: 1.